| Title |
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, September 2020
|
| DOI | 10.1158/1535-7163.mct-19-0958 |
| Pubmed ID | |
| Authors |
Mara Gilardi, Zhiyong Wang, Marco Proietto, Anastasia Chillà, Juan Luis Calleja-Valera, Yusuke Goto, Marco Vanoni, Matthew R Janes, Zbigniew Mikulski, Antonio Gualberto, Alfredo A Molinolo, Napoleone Ferrara, J Silvio Gutkind, Francis Burrows |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 45% |
| Switzerland | 1 | 9% |
| Unknown | 5 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 55% |
| Scientists | 4 | 36% |
| Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 26% |
| Researcher | 10 | 16% |
| Student > Bachelor | 4 | 6% |
| Student > Master | 3 | 5% |
| Student > Doctoral Student | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 22 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 16 | 26% |
| Medicine and Dentistry | 10 | 16% |
| Chemistry | 5 | 8% |
| Immunology and Microbiology | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Other | 4 | 6% |
| Unknown | 21 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 87. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 September 2021.
All research outputs
#423,317
of 23,225,652 outputs
Outputs from Molecular Cancer Therapeutics
#43
of 3,889 outputs
Outputs of similar age
#13,621
of 399,711 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#1
of 53 outputs
Altmetric has tracked 23,225,652 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,889 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,711 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.